GLPG1837: Ph II SAPHIRA 1 data

Top-line data from 26 CF patients with the G551D mutation in the open-label, international Phase II SAPHIRA 1 trial showed that twice-daily oral GLPG1837 significantly reduced mean sweat chloride leve...